Evaluation of Atezolizumab Monotherapy in Metastatic NSCLC patients
The Advent of immune checkpoint inhibitors has created a paradigm shift for the treatment of numerous malignancies. Inhibitors targeting Programmed Cell Death 1 (PD- 1) receptor and its ligand PD-L1, alone or in combination with chemotherapy drugs represent the new standard of treatment for difficult to treat malignancies such as non- small cell lung carcinoma (NSCLC).
A recent study by Herbst et al. evaluated the safety and efficacy of the anti-programmed death ligand-1 (PD-L1) monoclonal antibody, Atezolizumab, in metastatic NSCLC patients. Atezolizumab is marketed as TECENTRIQ by Genentech. Following sections provide a summary of the key findings presented in the study.
To evaluate the safety and efficacy of Atezolizumab as the first line treatment for metastatic NSCLC, as compared to platinum based chemotherapeutic compounds, among patient groups with varying levels of PD-L1 expression.
Key methods and patient characteristics
No of Pts
Pts with High PDL-1 Expression
Grade 3 or 4
Treatment with atezolizumab monotherapy resulted in longer overall survival than platinum- based chemotherapy among patients with NSCLC with high PDL1 expression
The published manuscript can be accessed at – https://www.nejm.org/doi/full/10.1056/NEJMoa1917346
Information Source: Herbst et al. Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC. New England Journal of Medicine, 2020 Oct 1;383(14):1328-1339. PMID: 32997907 DOI: 10.1056/NEJMoa1917346